Go online to PeerView.com/JPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This Clinical Consults activity features case-based expert discussions on the use of asparaginase in the context of broader innovations in ALL care across pediatric, A
Publish Date: Jul 15, 2021
There are currently no snippets from Nicola Gökbuget, MD - Achieving Therapeutic Innovation in ALL: Insights on Modern Asparaginase Compounds in Pediatric, AYA, and Adult Patien.
Snippets are an easy way to highlight your favorite soundbite from any piece of
audio and share with friends, or make a trailer for PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
There are currently no playlists containing this audio.
Add this audio track to one of your playlists
Go online to PeerView.com/JPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This Clinical Consults activity features case-based expert discussions on the use of asparaginase in the context of broader innovations in ALL care across pediatric, AYA, and adult patients. Our experts give insights on standard asparaginase compounds, monitoring and management of toxicities, hypersensitivity/silent inactivation, and sequential use of alternative asparaginase compounds. Upon completion of this accredited CE activity, participants should be better able to: Cite current, multimodal recommendations for acute lymphoblastic leukemia (ALL) management in pediatric, adolescents and young adult (AYA), and adult populations, including multi-agent chemotherapy and asparaginase compounds, antibody-based approaches, cellular therapy, and tyrosine kinase inhibitors, Discuss the clinical implications of Escherichia coli (E. coli) asparaginase hypersensitivity and asparaginase discontinuation in ALL, including in pediatric, AYA, and adult populations, Summarize evidence surrounding the use of Erwinia chrysanthemi asparaginase, including recombinant formulations as a component of chemotherapy for ALL, Apply updated protocols for the management of E. coli asparaginase hypersensitivity, including monitoring and strategies for switching to Erwinia asparaginase options.